Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021

VC Investment Tops 2020 Level, IPO Value Surges

Executive Summary

Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.

You may also be interested in...



Orum Taking Novel ADC Approach To Protein Degradation

Orum Therapeutics executives talk to Scrip on the next steps for the targeted protein degradation pioneer after a large-scale financing and on likely developments in the space in the coming years.

Standigm Races AI Rivals To Become Global Discovery Contender

The South Korean AI-driven drug discovery venture is vying with global rivals in the space to show concrete validation of its approaches in partnered projects, while eyeing international expansion and new fundraising, its CEO says.

SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook

Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel